argenx SE
Change company Symbol lookup
Select an option...
ARGX argenx SE
LULU Lululemon Athletica Inc
APT Alpha Pro Tech Ltd
PTC PTC Inc
AIC Arlington Asset Investment Corp
PSAGW Property Solutions Acquisition Corp II *W EXP 03/01/2026
AMZN Amazon.com Inc
GSK GlaxoSmithKline PLC
TSLA Tesla Inc
MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
Go

Health Care : Biotechnology | Mid Cap Growth
Based in Netherlands
Company profile

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Postmarket

Last Trade
Delayed
$293.74
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$293.74
Day's Change
-1.41 (-0.48%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
297.45
Day's Low
292.00
Volume
(Below Average)
Volume:
120,864

10-day average volume:
139,587
120,864

'Mixing' COVID-19 vaccines triggers a stronger immune response, preliminary NIH study says

4:24 pm ET October 13, 2021 (MarketWatch)
Print

Giving people a different COVID-19 booster than the vaccine series that they originally received is safe and generates an immune response that is stronger, according to a preprint study conducted by the National Institutes of Health. (At this time, only BioNTech (BNTX) and Pfizer Inc.'s (PFE) COVID-19 booster has been authorized for people who were previously vaccinated with that vaccine series.) The preprint, which was published Wednesday in advance of a public presentation set for Friday afternoon, evaluates all three authorized or approved COVID-19 vaccines in the U.S. in 458 participants as part of a "mix-and-match" clinical trial. With the exception of the people who were exclusively vaccinated and boosted with Johnson & Johnson's (JNJ) shots, all participants reported efficacy rates of at least 90.7%. "These data strongly suggest that homologous and heterologous booster vaccine will increase protective efficacy against symptomatic SARS-CoV-2 infection," the authors wrote. There are, however, some limitations to the research. The study is not randomized, and it also only assessed data available 29 days after the participants received their boosters.

-Jaimy Lee

	

(END) Dow Jones Newswires

October 13, 2021 16:24 ET (20:24 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.